From: Immunogenicity of panitumumab in combination chemotherapy clinical trials
Antibody Negative (N = 1317) | Antibody Positive (N = 65) | Predose Positive (N = 46) | Developing Antibody Positive (N = 21) | |
---|---|---|---|---|
Patients with any adverse event†, n (%) | 1312 (100) | 65 (100) | 46 (100) | 21 (100) |
Worst grade of 3‡ | 716 (54) | 26 (40) | 18 (39) | 8 (38) |
Worst grade of 4‡ | 264 (20) | 18 (28) | 15 (33) | 4 (19) |
Worst grade of 5‡ | 82 (6) | 6 (9) | 2 (4) | 4 (19) |
Any serious adverse event | 544 (41) | 32 (49) | 23 (50) | 10 (48) |
Patients with any adverse event leading to permanent discontinuation of any study drug, n (%) | 299 (23) | 16 (25) | 8 (17) | 8 (38) |
Not serious | 217 (16) | 12 (18) | 6 (13) | 6 (29) |
Serious | 108 (8) | 6 (9) | 3 (7) | 3 (14) |
Patients with any treatment-related adverse event§, n (%) | 1298 (99) | 65 (100) | 46 (100) | 21 (100) |
Worst grade of 3‡ | 739 (56) | 30 (46) | 20 (43) | 11 (52) |
Worst grade of 4‡ | 204 (15) | 15 (23) | 13 (28) | 2 (10) |
Worst grade of 5‡ | 13 (1) | 1 (2) | 0 | 1 (5) |
Any serious adverse event | 314 (24) | 20 (31) | 14 (30) | 6 (29) |
Patients with any adverse event leading to permanent discontinuation of any study drug, n (%) | 251 (19) | 11 (17) | 5 (11) | 6 (29) |
Not serious | 200 (15) | 9 (14) | 4 (9) | 5 (24) |
Serious | 64 (5) | 2 (3) | 1 (2) | 1 (5) |